SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales moved down -31.50% to Rs. 16898.30 millions for the December 2022 quarter as compared to Rs. 24667.70 millions during the corresponding quarter last year.A big decline of -65.73% was reported for the quarter ended December 2022 to Rs. 3109.00  millions from Rs. 9072.20 millions of corresponding previous quarter.Operating Profit reported a sharp decline to 5257.60 millions from 11165.20 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 16898.30 24667.70 -31.50 57171.30 63847.90 -10.46 88798.20 67986.10 30.61
Other Income 1163.40 166.20 600.00 2855.80 712.80 300.65 1112.60 625.30 77.93
PBIDT 5257.60 11165.20 -52.91 21418.40 28412.40 -24.62 39877.20 28832.10 38.31
Interest 1.10 2.00 -45.00 3.40 6.10 -44.26 6.50 6.90 -5.80
PBDT 5256.50 11163.20 -52.91 21415.00 28406.30 -24.61 39870.70 28825.20 38.32
Depreciation 865.40 797.00 8.58 2554.40 2298.00 11.16 3105.50 2546.50 21.95
PBT 4391.10 10366.20 -57.64 18860.60 26108.30 -27.76 36765.20 26278.70 39.90
TAX 1282.10 1294.00 -0.92 3967.00 5452.50 -27.24 7279.80 6731.50 8.15
Deferred Tax 236.30 102.00 131.67 646.30 527.40 22.54 907.80 641.00 41.62
PAT 3109.00 9072.20 -65.73 14893.60 20655.80 -27.90 29485.40 19547.20 50.84
Equity 530.90 530.90 0.00 530.90 530.90 0.00 530.90 530.90 0.00
PBIDTM(%) 31.11 45.26 -31.26 37.46 44.50 -15.81 44.91 42.41 5.89

Divis Lab Share Price

6228.95 -68.55 (-1.09%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×